$EYPT News

EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown

EyePoint: Still A Sell After Phase 3 Crash

These Analysts Slash Their Forecasts On EyePoint

Citigroup Maintains Buy on EyePoint, Lowers Price Target to $17

EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU - Slideshow

EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript

RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5

Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5

HC Wainwright & Co. Downgrades EyePoint to Neutral

JP Morgan Downgrades EyePoint to Neutral

Jefferies Maintains Buy on EyePoint, Lowers Price Target to $8

EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study

EyePoint Reports DURAVYU Non‑Inferior To Aflibercept In Ad Hoc Analysis; Primary BCVA Endpoint Not Met In Full Dataset

EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration

EyePoint: Phase 3 Design Creates A More Valuable Durability Story

Cantor Fitzgerald Maintains Overweight on EyePoint, Raises Price Target to $55

HC Wainwright & Co. Maintains Buy on EyePoint, Lowers Price Target to $27

EyePoint (NASDAQ:EYPT) Rallies Despite Wider Q2 Loss as Phase 3 Data Nears

EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate

EyePoint Pharmaceuticals To Pay $4.6M to Resolve False Claims Act Allegations